Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy (Archive) Wegovy pill expands US obesity share, but cash flow limits and GLP‑1 competition constrain upside.
Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It? (Archive) Novo Nordisk faces eroding GLP‑1 leadership, intensifying `1qcompetition, and mounting margin headwinds.
